203 related articles for article (PubMed ID: 28404893)
1. A varying-coefficient cox model for the effect of CA19-9 kinetics on overall survival in patients with advanced pancreatic cancer.
Chen Y; Shao Z; Chen W; Xie H; Wu Z; Qin G; Zhao N
Oncotarget; 2017 May; 8(18):29925-29934. PubMed ID: 28404893
[TBL] [Abstract][Full Text] [Related]
2. Application of a time-varying covariate model to the analysis of CA 19-9 as serum biomarker in patients with advanced pancreatic cancer.
Boeck S; Haas M; Laubender RP; Kullmann F; Klose C; Bruns CJ; Wilkowski R; Stieber P; Holdenrieder S; Buchner H; Mansmann U; Heinemann V
Clin Cancer Res; 2010 Feb; 16(3):986-94. PubMed ID: 20103662
[TBL] [Abstract][Full Text] [Related]
3. Prognostic value of serum CA19-9 in patients with advanced pancreatic cancer receiving gemcitabine based chemotherapy.
An X; Li YH; Lin XB; Wang FH; Feng F; Xu RH; Jiang WQ; He YJ
Ai Zheng; 2009 Mar; 28(3):286-91. PubMed ID: 19619444
[TBL] [Abstract][Full Text] [Related]
4. Combined pretreatment serum CA19-9 and neutrophil-to-lymphocyte ratio as a potential prognostic factor in metastatic pancreatic cancer patients.
Song JY; Chen MQ; Guo JH; Lian SF; Xu BH
Medicine (Baltimore); 2018 Jan; 97(4):e9707. PubMed ID: 29369199
[TBL] [Abstract][Full Text] [Related]
5. Prognostic relevance of CA 19-9, CEA, CRP, and LDH kinetics in patients treated with palliative second-line therapy for advanced pancreatic cancer.
Haas M; Laubender RP; Stieber P; Holdenrieder S; Bruns CJ; Wilkowski R; Mansmann U; Heinemann V; Boeck S
Tumour Biol; 2010 Aug; 31(4):351-7. PubMed ID: 20480409
[TBL] [Abstract][Full Text] [Related]
6. Prognostic significance of SUVmax and serum carbohydrate antigen 19-9 in pancreatic cancer.
Zhao JG; Hu Y; Liao Q; Niu ZY; Zhao YP
World J Gastroenterol; 2014 May; 20(19):5875-80. PubMed ID: 24914348
[TBL] [Abstract][Full Text] [Related]
7. The impact of resection margin status and postoperative CA19-9 levels on survival and patterns of recurrence after postoperative high-dose radiotherapy with 5-FU-based concurrent chemotherapy for resectable pancreatic cancer.
Kinsella TJ; Seo Y; Willis J; Stellato TA; Siegel CT; Harpp D; Willson JK; Gibbons J; Sanabria JR; Hardacre JM; Schulak JP
Am J Clin Oncol; 2008 Oct; 31(5):446-53. PubMed ID: 18838880
[TBL] [Abstract][Full Text] [Related]
8. Predictive Value of Serum Carbohydrate Antigen 19-9 (CA19-9) for Early Mortality in Advanced Pancreatic Cancer.
Usón Junior PLS; Callegaro-Filho D; Bugano DDG; Moura F; Maluf FC
J Gastrointest Cancer; 2018 Dec; 49(4):481-486. PubMed ID: 28924968
[TBL] [Abstract][Full Text] [Related]
9. The Combination of Neutrophil-to-lymphocyte Ratio and Serum Carbohydrate Antigen 19-9 Level as a Prognostic Indicator in Patients with Recurrent Pancreatic Cancer.
Sakamoto T; Saito H; Uchinaka EI; Morimoto M; Amisaki M; Tokuyasu N; Honjo S; Ashida K; Fujiwara Y
Anticancer Res; 2018 Sep; 38(9):5497-5503. PubMed ID: 30194208
[TBL] [Abstract][Full Text] [Related]
10. Carbohydrate antigen 19-9 is a prognostic and predictive biomarker in patients with advanced pancreatic cancer who receive gemcitabine-containing chemotherapy: a pooled analysis of 6 prospective trials.
Bauer TM; El-Rayes BF; Li X; Hammad N; Philip PA; Shields AF; Zalupski MM; Bekaii-Saab T
Cancer; 2013 Jan; 119(2):285-92. PubMed ID: 22786786
[TBL] [Abstract][Full Text] [Related]
11. Time to CA19-9 nadir: a clue for defining optimal treatment duration in patients with resectable pancreatic ductal adenocarcinoma.
Reni M; Peretti U; Zanon S; Macchini M; Balzano G; Mazza E; Tamburrino D; Orsi G; Arcidiacono PG; Falconi M; Gianni L
Cancer Chemother Pharmacol; 2020 Apr; 85(4):641-650. PubMed ID: 32157412
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of the neutrophil-to-lymphocyte ratio and carbohydrate antigen 19-9 in estimating survival in patients with metastatic pancreatic cancer.
Cetin S; Dede I
J Cancer Res Ther; 2020; 16(4):909-916. PubMed ID: 32930139
[TBL] [Abstract][Full Text] [Related]
13. CA19-9 as a predictor of tumor response and survival in patients with advanced pancreatic cancer treated with gemcitabine based chemotherapy.
Hammad N; Heilbrun LK; Philip PA; Shields AF; Zalupski MM; Venkatramanamoorthy R; El-Rayes BF
Asia Pac J Clin Oncol; 2010 Jun; 6(2):98-105. PubMed ID: 20565421
[TBL] [Abstract][Full Text] [Related]
14. Plasma microRNA192 in combination with serum CA19-9 as non-invasive prognostic biomarker in periampullary carcinoma.
Murali Manohar K; Sasikala M; Kvsrr Y; Sunil V; Talukdar R; Murthy H; Ramji C; Rao GV; Pradeep R; Reddy DN
Tumour Biol; 2017 Mar; 39(3):1010428317695018. PubMed ID: 28351309
[TBL] [Abstract][Full Text] [Related]
15. CA19-9-Low&Lewis (+) pancreatic cancer: A unique subtype.
Luo G; Liu C; Guo M; Long J; Liu Z; Xiao Z; Jin K; Cheng H; Lu Y; Ni Q; Yu X
Cancer Lett; 2017 Jan; 385():46-50. PubMed ID: 27840089
[TBL] [Abstract][Full Text] [Related]
16. Further evidence of the prognostic role of pretreatment levels of CA 19-9 in advanced pancreatic cancer.
Saad ED; Reis PT; Borghesi G; Machado MC; Simon SD; Tabacof J; Gansl RC
Rev Assoc Med Bras (1992); 2010; 56(1):22-6. PubMed ID: 20339781
[TBL] [Abstract][Full Text] [Related]
17. The prognostic and predictive value of serum CA19.9 in pancreatic cancer.
Humphris JL; Chang DK; Johns AL; Scarlett CJ; Pajic M; Jones MD; Colvin EK; Nagrial A; Chin VT; Chantrill LA; Samra JS; Gill AJ; Kench JG; Merrett ND; Das A; Musgrove EA; Sutherland RL; Biankin AV;
Ann Oncol; 2012 Jul; 23(7):1713-22. PubMed ID: 22241899
[TBL] [Abstract][Full Text] [Related]
18. Simple prognostic markers for optimal treatment of patients with unresectable pancreatic cancer.
Terao T; Kumagi T; Hyodo I; Yokota T; Azemoto N; Miyata H; Kuroda T; Ohno Y; Tanaka Y; Shibata N; Imamura Y; Kanemitsu K; Miyake T; Koizumi M; Hiasa Y;
Medicine (Baltimore); 2021 Oct; 100(43):e27591. PubMed ID: 34713835
[TBL] [Abstract][Full Text] [Related]
19. Serum dickkopf-1 is a novel serological biomarker for the diagnosis and prognosis of pancreatic cancer.
Han SX; Zhou X; Sui X; He CC; Cai MJ; Ma JL; Zhang YY; Zhou CY; Ma CX; Varela-Ramirez A; Zhu Q
Oncotarget; 2015 Aug; 6(23):19907-17. PubMed ID: 26101916
[TBL] [Abstract][Full Text] [Related]
20. CA19-9 for detecting recurrence of pancreatic cancer.
Azizian A; Rühlmann F; Krause T; Bernhardt M; Jo P; König A; Kleiß M; Leha A; Ghadimi M; Gaedcke J
Sci Rep; 2020 Jan; 10(1):1332. PubMed ID: 31992753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]